Kazia Therapeutics (KZIA) VP discloses initial ADS option grants

Rhea-AI Filing Summary

Kazia Therapeutics VP, Finance and Controller Jeffrey Bonacorda has reported initial holdings of stock options over American Depositary Shares. The filing shows options over 5,000 ADSs at an exercise price of 0.23 expiring on 2028-06-24, and options over 100,000 ADSs at 6.58 expiring on 2027-07-03. These awards vest in annual installments starting on June 24, 2024 and July 3, 2025, contingent on continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bonacorda Jeffrey

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS

LEVEL 24, 300 BARANGAROO AVE

(Street)

SYDNEY, NSW AUSTRALIA 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Finance and Controller

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Share Option (Right to Buy)	(1)	06/24/2028	American Depositary Shares(2)	5,000	$0.23	D
American Depositary Share Option (Right to Buy)	(3)	07/03/2027	American Depositary Shares(2)	100,000	$6.58	D

Explanation of Responses:

1. The American Depositary Shares ("ADSs") subject to the option ("ADS option") vest in four equal annual installments beginning on June 24, 2024, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on June 24, 2024.

2. Each ADS option is convertible into ADSs upon exercise. Each ADS may be represented by 500 ordinary shares of the Issuer, no par per share (the "Ordinary Shares"), at any time, upon the holder's election to surrender the ADSs and withdraw the respective number of Ordinary Shares. The ADSs have no expiration date.

3. The ADSs subject to the ADS option vest in three equal annual installments beginning on July 3, 2025, subject to the Reporting Person's continuous service relationship with the Issuer through each applicable vesting date. The ADS option was granted on July 3, 2025.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jeffrey Bonacorda	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Kazia Therapeutics (KZIA) Form 3 filing show for Jeffrey Bonacorda?

The Form 3 shows initial derivative holdings for VP, Finance and Controller Jeffrey Bonacorda. He holds options over 5,000 and 100,000 American Depositary Shares, with specified exercise prices and expiration dates, reflecting previously granted equity compensation rather than new market transactions.

How many Kazia Therapeutics (KZIA) ADS options does Jeffrey Bonacorda hold?

Jeffrey Bonacorda holds two ADS option grants: one over 5,000 American Depositary Shares and another over 100,000 American Depositary Shares. These options represent rights to buy ADSs at fixed exercise prices if vesting and other conditions are satisfied.

What are the exercise prices and expirations of KZIA options held by Jeffrey Bonacorda?

The filing lists exercise prices of 0.23 and 6.58 per ADS. The 5,000-ADS option expires on June 24, 2028, while the 100,000-ADS option expires on July 3, 2027, defining how long he can choose to exercise these awards.

How do the Kazia Therapeutics (KZIA) ADS options for Jeffrey Bonacorda vest?

The options vest in annual installments. The 0.23 exercise-price grant vests in four equal annual tranches starting June 24, 2024, and the 6.58 exercise-price grant vests in three equal annual tranches starting July 3, 2025, subject to continuous service.

What is the relationship between KZIA ADS options and ordinary shares mentioned in the filing?

Each ADS option converts into American Depositary Shares, and each ADS may represent 500 ordinary shares of Kazia Therapeutics. Holders can surrender ADSs to withdraw the corresponding ordinary shares, and the ADSs themselves have no expiration date according to the disclosure.

Does the KZIA Form 3 indicate any recent buying or selling by Jeffrey Bonacorda?

The Form 3 does not show open-market buys or sells. It reports existing option awards and their terms, categorized as holdings with unknown transaction codes, rather than new purchase or sale transactions in Kazia Therapeutics American Depositary Shares.